AACR 2022 | Opportunities for combination immunotherapies with TTX-030

Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, postulates on potential opportunities for advances in combination immunotherapies following positive interim results on a novel CD39 inhibitor, TTX-030. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.